BioDelivery Sciences Appoints Kevin Ostrander as Senior Vice President of Business Development
January 06 2020 - 8:30AM
BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly
growing specialty pharmaceutical company dedicated to patients
living with serious and complex chronic conditions, announced today
the appointment of Kevin Ostrander as Senior Vice President of
Business Development and member of the Company Executive Leadership
Team, effective today January 6. Mr. Ostrander brings nearly
thirty years of significant experience executing a multitude of
business development strategies, including in-licensing and
acquisition of products, establishing joint ventures and strategic
partnerships, and creating and running platform
collaborations.
“I am pleased to welcome Kevin to our rapidly growing Company,”
stated Herm Cukier, CEO of BDSI. “His profound experience in
completing more than 75 transactions over three decades is a great
addition to our leadership team as we build upon our strong growth
momentum into 2020 and beyond.”
“I am delighted to join BDSI during this time of rapid growth at
the Company and lead its business development efforts,” stated
Kevin Ostrander. “I am greatly looking forward to
capitalizing on the strengths of our organization to build a
broader portfolio of leading differentiated products that improve
the lives of patients living with serious and complex chronic
conditions.”
Kevin joins BDSI from Glenmark Pharmaceuticals where he was Head
of North America Business Development. He previously held
leadership positions in business and corporate development with a
diverse range of pharmaceutical and healthcare companies including
Mylan, Sandoz, Watson, and Cardinal Health. Kevin started his
career as a research and formulation scientist with companies such
as Elan and Nycomed. He holds a number of patents and has
authored several publications in tier one journals. Mr.
Ostrander received an MS from Temple University School of Pharmacy,
an MBA from St. Joseph’s University, and a Bachelor’s in Biology
from the State University of New York at Albany.
About BioDelivery Sciences
International, Inc.
BioDelivery Sciences International, Inc.
(NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical
company dedicated to patients living with chronic conditions. BDSI
has built a portfolio of products that includes utilizing its novel
and proprietary BioErodible MucoAdhesive (BEMA®) technology to
develop and commercialize, either on its own or in partnership with
third parties, new applications of proven therapies aimed at
addressing important unmet medical needs. BDSI's marketed products
address serious and debilitating conditions, including chronic
pain, opioid dependence, and opioid-induced constipation.
Cautionary Note on Forward-Looking
Statements
This press release and any statements of
employees, representatives, and partners of BDSI related thereto
contain, or may contain, among other things, certain
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve significant risks and uncertainties. Such
statements may include, without limitation, statements with respect
to the BDSI’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential” or similar expressions. These statements are based upon
the current beliefs and expectations of the BDSI’s management and
are subject to significant risks and uncertainties, including those
detailed in the BDSI’s filings with the Securities and Exchange
Commission. Actual results may differ materially from those set
forth or implied in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the BDSI’s control) including those set forth in our
2018 annual report on Form 10-K filed with the US Securities and
Exchange Commission and subsequent filings. BDSI undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
© 2020 BioDelivery Sciences International,
Inc. All rights reserved.
Contact:Tirth T. PatelDirector
of Investor Relationstpatel@bdsi.com(919) 582-0294
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Apr 2024 to May 2024
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From May 2023 to May 2024